TY - JOUR
T1 - Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness?
T2 - A Systematic Review
AU - Orsolini, Laura
AU - Sarchione, Fabiola
AU - Vellante, Federica
AU - Fornaro, Michele
AU - Matarazzo, Ilaria
AU - Martinotti, Giovanni
AU - Valchera, Alessandro
AU - Di Nicola, Marco
AU - Carano, Alessandro
AU - Di Giannantonio, Massimo
AU - Perna, Giampaolo
AU - Olivieri, Luigi
AU - De Berardis, Domenico
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: Schizophrenia is a complex illness in which genetic, environmental, and epigenetic components have been implicated. However, recently, psychiatric disorders appear to be related to a chronic inflammatory state, at the level of specific cerebral areas which have been found as well impaired and responsible for schizophrenia symptomatology. Hence, a role of inflammatory mediators and cytokines has been as well defined. Accordingly, the role of an acute inflammatory phase protein, the C-reactive protein (CRP) has been recently investigated. Objective: The objective of the present study is to evaluate how PCR may represent a biomarker in schizophrenia, i.e. correlated with illness phases and/or clinical manifestation and/or psychopathological severity. Methods: A systematic review was here carried out by searching the following keywords ((C-reactive protein AND ((schizophrenia) OR (psychotic disorder))) for the topics 'PCR' and 'Schizophrenia', by using MESH terms. Results: An immune dysfunction and inflammation have been described amongst schizophrenic patients. Findings reported elevated CRP levels in schizophrenia, mainly correlated with the severity of illness and during the recrudescent phase. CRP levels are higher when catatonic features, negative symptomatology and aggressiveness are associated. CRP levels appeared not to be related to suicidal behaviour and ideation. Conclusion: CRP and its blood levels have been reported higher amongst schizophrenic patients, by suggesting a role of inflammation in the pathogenesis of schizophrenia. Further studies are needed to better understand if CRP may be considered a biomarker in schizophrenia.
AB - Background: Schizophrenia is a complex illness in which genetic, environmental, and epigenetic components have been implicated. However, recently, psychiatric disorders appear to be related to a chronic inflammatory state, at the level of specific cerebral areas which have been found as well impaired and responsible for schizophrenia symptomatology. Hence, a role of inflammatory mediators and cytokines has been as well defined. Accordingly, the role of an acute inflammatory phase protein, the C-reactive protein (CRP) has been recently investigated. Objective: The objective of the present study is to evaluate how PCR may represent a biomarker in schizophrenia, i.e. correlated with illness phases and/or clinical manifestation and/or psychopathological severity. Methods: A systematic review was here carried out by searching the following keywords ((C-reactive protein AND ((schizophrenia) OR (psychotic disorder))) for the topics 'PCR' and 'Schizophrenia', by using MESH terms. Results: An immune dysfunction and inflammation have been described amongst schizophrenic patients. Findings reported elevated CRP levels in schizophrenia, mainly correlated with the severity of illness and during the recrudescent phase. CRP levels are higher when catatonic features, negative symptomatology and aggressiveness are associated. CRP levels appeared not to be related to suicidal behaviour and ideation. Conclusion: CRP and its blood levels have been reported higher amongst schizophrenic patients, by suggesting a role of inflammation in the pathogenesis of schizophrenia. Further studies are needed to better understand if CRP may be considered a biomarker in schizophrenia.
KW - C-reactive protein
KW - schizophrenia
KW - psychosis
KW - inflammation
KW - chronic illness
KW - systematic review
KW - PROSPECTIVE BIRTH COHORT
KW - SUBSTANCE USE DISORDERS
KW - BIPOLAR DISORDER
KW - INFLAMMATORY MARKERS
KW - OXIDATIVE STRESS
KW - COGNITIVE IMPAIRMENT
KW - ADULT SCHIZOPHRENIA
KW - SERUM-LEVELS
KW - CARDIOVASCULAR-DISEASE
KW - UNIPOLAR DEPRESSION
U2 - 10.2174/1570159X16666180119144538
DO - 10.2174/1570159X16666180119144538
M3 - (Systematic) Review article
C2 - 29357805
SN - 1570-159X
VL - 16
SP - 583
EP - 606
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 5
ER -